ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Revenue of ImmunoGen, Inc. (IMGN)
Revenue in 2022 (TTM): $108.78 M
According to ImmunoGen, Inc.'s latest financial reports the company's current revenue (TTM) is $108.78 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ImmunoGen, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $108.78 M | $108.61 M | $-217,546,000 | $-221,711,000 | $-222,929,000 |
| 2021 | $108.78 M | $108.61 M | $-217,546,000 | $-221,711,000 | $-222,929,000 |
| 2020 | $132.3 M | $17.71 M | $-19,683,000 | $-44,372,000 | $-66,683,000 |
| 2019 | $82.27 M | $-32,251,000 | $-65,726,000 | $-104,133,000 | $-122,093,000 |
| 2018 | $53.82 M | $-120,070,000 | $-153,454,000 | $-167,873,000 | $-167,873,000 |
| 2017 | $115.45 M | $-24,292,000 | $-55,596,000 | $-96,012,000 | $-96,012,000 |
| 2016 | $48.63 M | $-92,684,000 | $-125,198,000 | $-156,733,000 | $-156,733,000 |
| 2015 | $60 M | $-86,913,000 | $-123,525,000 | $-143,655,000 | $-143,655,000 |
| 2014 | $85.54 M | $-26,227,000 | $-55,303,000 | $-60,739,000 | $-60,739,000 |
| 2013 | $59.9 M | $-47,062,000 | $-71,531,000 | $-71,364,000 | $-71,364,000 |
| 2012 | $35.54 M | $-51,538,000 | $-73,009,000 | $-72,811,000 | $-72,811,000 |
| 2011 | $16.36 M | $16.36 M | $-73,195,000 | $-73,319,000 | $-73,319,000 |
| 2010 | $19.31 M | $19.31 M | $-62,102,000 | $-58,274,000 | $-58,274,000 |
| 2009 | $13.94 M | $13.94 M | $-51,293,000 | $-51,177,000 | $-50,912,000 |
| 2008 | $27.99 M | $27.99 M | $-31,595,000 | $-32,037,000 | $-31,937,000 |
| 2007 | $40.25 M | $40.25 M | $-32,298,000 | $-31,993,000 | $-32,020,000 |
| 2006 | $38.21 M | $34.64 M | $-22,347,000 | $-18,953,000 | $-18,987,000 |
| 2005 | $32.09 M | $29.42 M | $-18,993,000 | $-17,817,000 | $-17,834,000 |
| 2004 | $35.72 M | $26.48 M | $-10,527,000 | $-10,922,000 | $-10,951,000 |
| 2003 | $25.96 M | $20.3 M | $-8,589,219 | $-5,871,741 | $-5,916,741 |
| 2002 | $7.63 M | $4.79 M | $-25,424,924 | $-19,947,183 | $-19,982,308 |
| 2001 | $5.88 M | $2.54 M | $-20,568,350 | $-14,502,027 | $-14,629,839 |
| 2000 | $4.48 M | $3.88 M | $-15,663,903 | $-9,473,604 | $-15,290,682 |
| 1999 | $11.18 M | $11.64 M | $-366,607 | $-237,560 | $-237,560 |
| 1998 | $3.7 M | $4.2 M | $-3,800,000 | $-4,100,000 | $-4,100,000 |
| 1997 | $600 K | $1.7 M | $-6,600,000 | $-7,600,000 | $-7,600,000 |
| 1996 | $400 K | $1.9 M | $-7,900,000 | $-9,000,000 | $-9,000,000 |
| 1995 | $500 K | $6.5 M | $-3,000,000 | $-16,500,000 | $-16,500,000 |
| 1994 | $500 K | $-12,900,000 | $-15,900,000 | $-19,900,000 | $-19,900,000 |
| 1993 | $900 K | $-17,000,000 | $-21,500,000 | $-23,700,000 | $-23,700,000 |
| 1992 | $1.7 M | $3.4 M | $-16,800,000 | $-18,600,000 | $-18,600,000 |
| 1991 | $2.7 M | $4 M | $-14,000,000 | $-15,300,000 | $-15,300,000 |
| 1990 | $3.4 M | $-6,100,000 | $-7,500,000 | $-8,700,000 | $-8,800,000 |
| 1989 | $1000 K | $-6,100,000 | $-7,500,000 | $-8,300,000 | $-8,300,000 |
| 1988 | $800 K | $-3,900,000 | $-4,900,000 | $-5,300,000 | $-5,300,000 |